|
| Researcher | Diagnostic criteria | Sample size | Intervention | Follow-up period | Outcome |
| Experiment | Control | Experiment | Control |
|
| Jingyuan Mao | Ischemic heart disease with LVEF ≤45%, NYHA II–IV | 319 | 319 | Qishen Yiqi dripping pills + standard treatment | Placebo + standard treatment | 6 months | Increased 6-minute walking distance, improved the quality of life |
| Xinli Li | Chinese guidelines for the diagnosis and management of CHF, LVEF ≤ 40% and a serum NT-proBNP level 450 pg/ml | 256 | 256 | Qili Qiangxin capsules + standard treatment | Placebo + standard treatment | 12 weeks | Reduced NT-proBNP level, improved NYHA functional classification, LVEF and 6-min walking distance |
| Chen Wang | The Framingham HF diagnostic criteria + TCM syndrome differentiation | 138 | 127 | Shencao Tongmai granule + standard treatment | Placebo + standard treatment | 12 weeks | Improved NYHA functional classification and LVEF |
| Shaoxiang Xian | CHF combined with CAD, NYHA functional classification II–IV + TCM syndrome differentiation | 120 | 120 | Shenmai injection + standard treatment | Placebo + standard treatment | 7 days | Improved NYHA functional classification, and 6-minute walking distance and TCM syndrome score |
| Shao-Xiang Xian | Clinical cardiology, 3200 medical
Disease diagnostic Criteria + TCM syndrome differentiation | 116 | 112 | Yangxinkang tablets + standard treatment | Placebo + standard treatment | 4 weeks | Improved the quality of life and symptoms |
| Jingui Xue | ACCF/AHA guidelines for the diagnosis and management of heart failure in adults | 50 | 50 | Xinmailong injection + standard treatment | Placebo + standard treatment | 5 days | Reduced BNP, improved NYHA functional classes and LVEF |
| Ju-Hsin Cheng | AHA guidelines for the diagnosis and management of heart failure in adults, NYHA functional classification II | 50 | 50 | Chan-Chuang Qigong | Blank control | 12 weeks | Improved the quality of life and 6-minute walking distance |
|
